PMV Pharmaceuticals reports news as a precision oncology company developing small molecule therapies that target p53. Its recurring updates center on rezatapopt, an oral product candidate designed to reactivate mutant p53 in tumors with the TP53 Y220C mutation, and on the PYNNACLE clinical trial in advanced solid tumors, including ovarian cancer.
Company announcements also cover clinical data presentations and publications, FDA designation activity, periodic financial results, research and development spending tied to rezatapopt, cash runway commentary, and board governance changes.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported its third quarter financial results for 2022, detailing ongoing efforts in the PYNNACLE study of PC14586, aimed at treating advanced solid tumors with a p53 Y220C mutation. The company had $258.9 million in cash as of September 30, 2022, down from $314.1 million at the end of 2021. R&D expenses rose to $37.0 million while net loss increased to $54.0 million. The company is also set to initiate a Phase 1b trial of PC14586 in combination with KEYTRUDA.
PMV Pharmaceuticals (Nasdaq: PMVP) announced the appointment of Carol Gallagher, Pharm.D., to its Board of Directors, replacing Thilo Schroeder, Ph.D. Dr. Gallagher brings over 30 years of experience in biotech leadership and drug commercialization. She currently serves as a venture partner at NEA and is a director at Atara Biotherapeutics. Gallagher highlighted the company's recent clinical proof of concept for its lead candidate, PC14586, as a significant advancement in developing targeted therapies for cancer patients.
PMV Pharmaceuticals (Nasdaq: PMVP) reported promising Phase 1 data for PC14586, a first-in-class p53 Y220C reactivator, presented at the ASCO annual meeting. The data indicated significant clinical activity across various solid tumors. PMV Pharma has partnered with Merck to evaluate PC14586 with KEYTRUDA®, with trials launching in Q4 2022. Financially, PMV had $277.4 million in cash as of June 30, 2022, down from $339.0 million a year prior. The company recorded a net loss of $35.7 million for the first half of 2022, compared to $24.5 million in 2021, driven by increased R&D and G&A expenses.
PMV Pharmaceuticals has announced a collaboration with Merck to initiate a combination trial in Q4 2022, evaluating PC14586 alongside Merck's KEYTRUDA for treating advanced solid tumors with a p53 Y220C mutation. This endeavor is part of the ongoing Phase 1/2 PYNNACLE trial, with 36 patients expected to enroll in the combination arm. The trial aims to assess safety, tolerability, and preliminary efficacy, building on encouraging monotherapy results presented at ASCO 2022. PC14586 is a pioneering small molecule designed to reactivate the p53 protein.
PMV Pharmaceuticals (Nasdaq: PMVP) announced that its CEO, David H. Mack, will join a fireside chat at the Goldman Sachs Global Healthcare Conference from June 14-16, 2022, in California. The chat is scheduled for June 14 at 1:20 p.m. PDT. PMV Pharma focuses on precision oncology, developing therapies targeting p53 mutations, which occur in about half of all cancers. The company will also conduct one-on-one meetings with institutional investors during the event. For more details, visit www.pmvpharma.com.
PMV Pharmaceuticals (PMVP) announced promising preliminary results from the Phase 1/2 PYNNACLE study of PC14586, a groundbreaking therapy targeting the p53 Y220C mutation in various advanced solid tumors. The overall response rate (ORR) is 32% in higher dose cohorts, with responses noted across six tumor types. The safety profile is deemed acceptable, with the maximum tolerated dose established at 1500 mg twice daily. The results were presented at ASCO, indicating potential for PC14586 as a new treatment option for patients with specific oncogenic mutations.
PMV Pharmaceuticals (PMVP) announced preliminary results from its ongoing Phase 1/2 PYNNACLE trial of PC14586, targeting the p53 Y220C mutation in advanced solid tumors. The ASCO abstract highlights a 30% partial response rate in higher dose cohorts among 29 patients. The drug demonstrated a favorable safety profile with well-tolerated doses. Updated data will be presented on June 7, 2022, during an oral session at ASCO, followed by an investor event to discuss the findings. The trial indicates potential for PC14586 as a targeted therapy in oncology.
PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) reported Q1 2022 financial results, highlighting $294.8 million in cash and a net loss of $18.4 million. R&D expenses increased to $11.8 million, driven by advancing PC14586, a first-in-class p53 Y220C reactivator. General and administrative costs rose to $6.8 million, reflecting infrastructure growth as a public company. The company emphasized its focus on executing the Phase 1/2 PYNNACLE trial and presenting initial data at the 2022 ASCO meeting on June 7.
PMV Pharmaceuticals (PMVP) has announced that initial data from its ongoing Phase 1 study of PC14586 will be presented at the 2022 ASCO Annual Meeting. This investigational therapy targets patients with advanced solid tumors featuring a p53 Y220C mutation. The oral presentation is scheduled for June 7, 2022, at 9:45 AM CDT, under the title 'First-in-human study of PC14586.' PC14586 aims to restore the normal function of p53 proteins, pivotal in cancer suppression. Detailed insights will be shared regarding its progress in the clinical trial process.
PMV Pharmaceuticals (PMVP) has made significant progress in its Phase 1/2 trial of PC14586, targeting advanced solid tumors with p53 Y220C mutations. As of December 31, 2021, the company reported a cash position of $314.1 million, down from $361.4 million in 2020. The net loss for 2021 was $57.8 million, an increase from $34.4 million in 2020, largely due to higher R&D and G&A expenses. While patient enrollment continues on track, the company anticipates initial results from the trial in mid-2022, aiming to expand its pipeline with additional p53-targeting therapies.